Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. (ADVM) Revenue
Annual & quarterly revenue history · segment & region breakdown
ADVM · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAdverum Biotechnologies, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 72.22% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | -$0.00B | -72.22% |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | -$0.01B | -100.00% |
| 2021-12-31 | $0.01B | +$0.01B | — |
| 2020-12-31 | $0.00B | -$0.00B | -100.00% |
| 2019-12-31 | $0.00B | -$0.00B | -84.49% |
| 2018-12-31 | $0.00B | -$0.00B | -12.82% |
| 2017-12-31 | $0.00B | +$0.00B | +27.08% |
| 2016-12-31 | $0.00B | -$0.00B | -37.26% |
| 2015-12-31 | $0.00B | +$0.00B | +305.42% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Adverum Biotechnologies, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Adverum Biotechnologies, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Adverum Biotechnologies, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ADVM revenue · 4 questionsADVM's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 72.22% year-over-year from $0.00B in FY2024.
▸ Source: FMP · Adverum Biotechnologies, Inc. SEC filings · GAAP · Adverum Biotechnologies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026